Bulletin
Investor Alert

Dec. 1, 2021, 4:45 p.m. EST

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of BeyondSpring Inc. (BYSI) Investigation

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    BeyondSpring Inc. (BYSI)

or Cancel Already have a watchlist? Log In

December 01, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / December 1, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BeyondSpring Inc. ("BeyondSpring" or the "Company") /zigman2/quotes/204570570/composite BYSI +8.33% . Investors who purchased BeyondSpring sharesare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bysi .

Image: https://www.accesswire.com/users/newswire/images/672396/Bron.png

The investigation concerns whether BeyondSpring and certain of its officers and/or directors have violated federal securities laws.

On December 1, 2021, BeyondSpring issued a press release "announc[ing] it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form." BeyondSpring stated that "[t]he FDA's CRL indicated that the results of the single registrational trial (106 Phase 3) was not sufficiently robust to demonstrate benefit and that a second well controlled trial would be required to satisfy the substantial evidence requirement to support the CIN indication." On this news, BeyondSpring's stock price fell sharply during intraday trading on December 1, 2021.

If you are aware of any facts relating to this investigation or purchased BeyondSpring shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/bysi . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:

https://www.accesswire.com/675630/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-BeyondSpring-Inc-BYSI-Investigation

COMTEX_398108338/2457/2021-12-01T16:45:28

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

/zigman2/quotes/204570570/composite
US : U.S.: Nasdaq
$ 1.56
+0.12 +8.33%
Volume: 240,091
July 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$56.06 million
Rev. per Employee
$17,776
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.